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Introduction
Prader-Willi syndrome (PWS) is a congenital disorder
characterized by short stature, childhood-onset obesity,
hyperphagia, neonatal hypotonia, hypogonadism, devel-
opmental delay, typical facial appearance, and behavioral
problems.1–6 Most patients have hypothalamic-pituitary
dysfunction and growth hormone (GH) deficiency.7,8
The genetic basis of PWS is loss of paternal gene
expression in the PWS-critical region on 15q11-13.
Approximately 70–75% of cases result from deletion of
this region in the paternal chromosome 15, 25–28%
from maternal uniparental disomy (UPD), and 2–5%
from a mutation or deletion in the imprinting center
or other imprinting defect.9 The most common dys-
morphic features of PWS are short stature and obesity.
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Data from short-term10–17 and longer-term studies18–21
in Western countries have shown that GH therapy im-
proves growth rate and body composition. However,
information regarding the long-term efficacy of GH
treatment for Asian PWS patients is limited.22 Thus,
the aim of this study was to evaluate whether GH treat-
ment could improve growth rate, standard deviation
score (SDS) of height, weight and body mass index
(BMI), and Rohrer index.
Methods
Subject selection
Forty-six patients with PWS (27 males, 19 females; age
range, 1 year 4 months to 13 years 7 months) who
received and/or who are currently receiving GH treat-
ment (0.1 IU/kg/day subcutaneously) from August
2002 through June 2007 in 8 medical centers in Taiwan
were enrolled in this study. These medical institutions
were Mackay Memorial Hospital, Taipei Tzu Chi
Hospital, Kaohsiung Medical University Hospital,
China Medical University Hospital, Kaohsiung Veterans
General Hospital, Cathay General Hospital, Chang-
Gung Children’s Hospital and Taipei City Hospital.
GH treatment was started at between 2 months and
10 years 10 months of age. The duration of GH therapy
ranged from 1 year to 4 years and 11 months. For each
patient, an informed written consent was signed by at
least 1 parent. Each patient received a complete genetic
analysis. The study was approved by the ethics commit-
tee of Mackay Memorial Hospital, Taipei, Taiwan.
Data and statistical analyses
We compared height, weight, BMI (weight in kg
divided by height in meters squared) and Rohrer index
(weight in kg divided by height in meters cubed × 10)
before and after GH treatment. SDS was derived by
subtracting the population mean from an individual raw
score and then dividing the difference by the population
standard deviation. Height, weight and BMI were also
calculated as SDS according to the standard growth
tables for Taiwanese children.23–25 Two-tailed paired 
t statistics were used to test for statistical significance.
The effects of gender and genotype pattern on
changes in height SDS, weight SDS, BMI SDS and
Rohrer index after GH treatment were analyzed using
2-way analysis of variance (ANOVA), with gender
(males vs. females) and genotype pattern (deletion vs.
UPD) as main effects. Differences were considered to
be statistically significant when p < 0.05.
Results
The clinical profiles of the 46 participants are summa-
rized in Table 1. The mean age at the start of GH treat-
ment was 4.3±3.0 years. With regard to the underlying
genetic defect, deletion was found in 35 (76%) patients,
maternal UPD in 9 (20%), and an imprinting center
deletion or an imprinting defect in 2 (4%).
Changes in growth rate for children 
beyond 3 years of age
The growth velocity of children reaches its highest value
during the first 2–3 years of life before puberty, and
slows to about 6 cm/year during middle childhood.26
In order to minimize the statistical bias, we selected
children beyond 3 years of age and before puberty
(30 cases) to depict the curve of height velocity before
and during GH treatment (Figure 1). After patients
had received GH treatment for 1, 2 and 3 years, their
height velocities improved from 4.00 ± 1.92 to 10.36 ±
2.37 cm/year (p < 0.001), 7.47 ± 1.68 cm/year (p <
0.001), and 6.38±1.31cm/year (p<0.05), respectively.
Changes in height SDS, weight SDS, BMI 
SDS and Rohrer index
After patients had received GH treatment for 1, 2 and
3 years, height SDS improved from −1.24 ± 1.44 to 
−0.31 ± 1.25 (p < 0.01), 0.00 ± 1.11 (p < 0.001), and
−0.26 ± 0.43 (p < 0.001), respectively (Figure 2A).
Weight SDS changed non-significantly from 1.11±2.36
to 1.26 ± 2.41 (p > 0.05) and to 0.98 ± 1.12 (p > 0.05)
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Table 1. Profiles of 46 patients with Prader-Willi syndrome receiving growth hormone treatment
Parameter Baseline (n = 46) 1 year (n = 46) p 2 years (n = 39) p 3 years (n = 17) p
BH SDS −1.24 ± 1.44 −0.31 ± 1.25 < 0.01 0.00 ± 1.11 < 0.001 −0.26 ± 0.43 < 0.001
BW SDS 1.11 ± 2.36 1.26 ± 2.41 NS 1.47 ± 2.15 NS 0.98 ± 1.12 NS
BMI SD 1.93 ± 2.24 1.13 ± 2.29 < 0.05 1.44 ± 2.06 NS 1.09 ± 1.27 NS
Rohrer index (kg/m3) 224.2 ± 35.2 186.6 ± 35.6 < 0.001 178.9 ± 63.3 < 0.001 169.3 ± 86.7 < 0.001
BH = body height; SDS = standard deviation score; BW = body weight; BMI = body mass index; NS = not significant.
after 1 year and 3 years of GH treatment, respectively
(Figure 2B). In contrast, BMI SDS showed a signifi-
cant decrease from 1.93±2.24 to 1.13±2.29 (p<0.05)
after 1 year of treatment, but exhibited no significant
differences afterwards (Figure 2C). The Rohrer index
decreased significantly from 224.2 ± 35.2 to 186.6 ±
35.6 (p < 0.001) at year 1, and to 178.9 ± 63.3 (p <
0.001) at year 2, and to 169.3 ± 86.7 (p < 0.001) at
year 3 of treatment (Figure 2D).
Analysis of response to GH treatment
No significant gender or genotype pattern effect was
found for any of the growth parameters analyzed.
Adverse events
One child died while receiving GH treatment. She
had been treated with GH for more than 23 months.
She died at the age of 6 years and 1 month due to pneu-
monia with respiratory failure. In our study, no child
developed diabetes mellitus or scoliosis while receiving
GH treatment.
Discussion
This study was a retrospective analysis of 46 cases of
PWS collected over a 5-year period (2002–2007) in 
8 medical centers in Taiwan. Earlier studies in Western
countries had demonstrated the clinical benefits of GH
therapy in children with PWS, including improvement
of linear growth, body composition, fat utilization,
physical strength and agility.10–21 The response to GH
therapy of children with PWS was greatest during the
first 12 months in relation to increased linear growth
rate, decreased body fat, and increased lean body mass.
However, between months 12 and 36, the growth rate
slowed down; these results were consistent with those
of previous longer-term studies.18–22 This reduction
in response to GH therapy has also been documented
in other disorders treated with prolonged GH ther-
apy, such as Turner syndrome, intrauterine growth
restriction, chronic renal failure, and idiopathic short
stature.27–29
In our study, the improvement of height SDS was
still statistically significant after 3 years of GH therapy,
which indicated that the efficacy of GH lasted for at
least 3 years. Our data demonstrate that although GH
therapy did not give rise to statistically significant
changes in weight SDS, there was a significant decrease
in BMI SDS in the first year of treatment. These find-
ings are in agreement with those reported by Obata
et al,22 Davies et al15 and Lindgren and Ritzen.20
Although Mei et al30 reported that for children and
adolescents aged 2–19 years, the performance of BMI-
for-age was better than that of Rohrer index-for-age in
predicting overweight, some evidence still showed that
the Rohrer index was independent of age, and repre-
sents a better parameter than BMI in predicting body
fatness from childhood through adolescence.22,31 In
comparison with BMI, which generally increases with
age from childhood through adolescence,32 it indicates
that improvement in Rohrer index showed an actual
improvement of obesity. Generally, Rohrer index is one
of the parameters to predict body fatness in children.
Our study indicates that GH therapy led to a significant
decrease in Rohrer index, suggesting that GH treat-
ment probably improved the degree of obesity in
patients with PWS. This finding is in accordance with
that of Obata et al.22
The study of Obata et al22 showed that PWS males
might gain more height than PWS females with GH
therapy. They compared the mean final height of male
and female patients with GH therapy to those without
GH therapy, finding 10.3 cm and 6.5 cm gains, respec-
tively, after GH treatment. However, in our 1-year data,
we did not find significant difference in height SDS
change between male and female patients. More longer-
term studies are required to clarify this point. To the
best of our knowledge, our study provides the first evi-
dence that no significant genotype pattern difference
was noted among the 4 parameters examined.
Sudden unexpected deaths were reported in patients
with PWS who received GH therapy, and the causes
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Figure 1. Height velocity for children with Prader-Willi syndrome
beyond 3 years of age and before puberty (30 cases) before and
during growth hormone therapy. Significant differences versus −1
year are indicated at 1, 2 and 3 years by *p < 0.001 or †p < 0.05.
remained diverse, including bronchopneumonia, res-
piratory insufficiency and sleep apnea.16,33 Our patient
died at the age of 6 years and 1 month due to pneumo-
nia with respiratory failure after receiving GH therapy
for more than 23 months. Scoliosis and diabetes melli-
tus were the most commonly reported adverse effects,16
but we did not find such events at the time of this
study.
PWS is not an indication for GH treatment in
many countries, so long-term data on final height and
safety are at present limited.16 The limitations of our
data were that it was a retrospective and uncontrolled
study, however, it is the first report of GH therapy in
Taiwanese patients with PWS. Since May 2004, GH
therapy has been endorsed by the National Health
Insurance for the treatment of PWS in Taiwan.
More long-term efficacy and safety data will be
needed to determine whether GH treatment in chil-
dren with PWS actually improves their quality of life.
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